MAP3K1 Rs889312 Genotypes Influence Survival Outcomes of Chinese Gastric Cancer Patients Who Received Adjuvant Chemotherapy Based on Platinum and Fluorouracil Regimes

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Nov 6

PMID 31686841

Citations 1

Authors

Jian Yang

Wei Zheng

Zhi Xu

Jinfei Chen

Affiliations

Soon will be listed here.

Abstract

Background: For patients with gastric cancer (GC), adjuvant chemotherapy is a standard therapy. However, the responses to the treatment are quite different. Mitogen-activated protein kinase (MAPK) pathway is a core pathway that modulates the efficacy of anticancer drugs. The purpose of our study was to investigate the clinical significance of one pivotal functional gene polymorphism in the MAPK pathway - MAP3K1 rs889312 - in patients with stage II GC to stage III GC.

Methods: The genotypes of MAP3K1 rs889312 were analyzed in 591 GC patients enrolled in this study who had received radical gastrectomy. Among them, 204 patients accepted adjuvant chemotherapy based on platinum and ﬂuorouracil (PF) regimens after an operation. Cox regression analysis, log-rank test and Kaplan-Meier method were used to explore the link between MAP3K1 rs889312 variant and overall survival (OS) of GC.

Results: Compared with the AA genotype (mean OS of 68.12 months), MAP3K1 rs889312 AC/CC significantly reduced the mean OS of 56.83 months in patients who received adjuvant chemotherapy only. In addition, AC/CC genotype had a negative impact on OS of patients who received oxaliplatin-based therapy (HR, 8.253; 95% CI: 1.119-60.853, log-rank =0.013). Stratification analysis showed that MAP3K1 rs889312 AC/CC significantly reduced OS of patients with tumors smaller than or equal to 5 cm in size (HR, 3.706; 95% CI: 1.329-10.335, =0.012), poorly differentiated tumors (HR, 3.002; 95% CI: 1.076-8.377, =0.036) and intestinal tumors (HR, 4.780; 95% CI: 1.138-20.073, =0.033).

Conclusion: Our findings suggested that MAP3K1 rs889312 single-nucleotide polymorphism may be considered as a biomarker for adjuvant chemotherapy reaction and can predict prognosis of GC patients who received PF-based therapy.

Citing Articles

MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta-analysis.

Aziz M, Islam M Cancer Rep (Hoboken). 2022; 6(1):e1773.

PMID: 36560873 PMC: 9875638. DOI: 10.1002/cnr2.1773.

References

Nussinov R, Tsai C, Jang H . A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. Trends Pharmacol Sci. 2017; 38(5):427-437. PMC: 5403593. DOI: 10.1016/j.tips.2017.02.001. View

Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J . Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res. 2014; 164(5):411-23. DOI: 10.1016/j.trsl.2014.06.005. View

Ma G, Gu D, Lv C, Chu H, Xu Z, Tong N . Genetic variant in 8q24 is associated with prognosis for gastric cancer in a Chinese population. J Gastroenterol Hepatol. 2014; 30(4):689-95. DOI: 10.1111/jgh.12801. View

Ende T, Ter Veer E, Machiels M, Mali R, Abe Nijenhuis F, de Waal L . The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers (Basel). 2019; 11(1). PMC: 6356558. DOI: 10.3390/cancers11010080. View

Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q . p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2013; 344(2):174-9. DOI: 10.1016/j.canlet.2013.11.019. View

Kuo S, Yang S, You S, Lien H, Lin C, Lin P . Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget. 2017; 8(13):20925-20938. PMC: 5400556. DOI: 10.18632/oncotarget.14995. View

Wang Q, Shi Y, Zhou K, Wang L, Yan Z, Liu Y . PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018; 9(7):739. PMC: 6030128. DOI: 10.1038/s41419-018-0776-6. View

Zhang X, Zhu H, Wu X, Wang M, Gu D, Gong W . A genetic polymorphism in TOX3 is associated with survival of gastric cancer in a Chinese population. PLoS One. 2013; 8(9):e72186. PMC: 3775787. DOI: 10.1371/journal.pone.0072186. View

Xu Z, Zhu H, Luk J, Wu D, Gu D, Gong W . Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer. Cancer. 2012; 118(22):5489-96. DOI: 10.1002/cncr.27599. View

10.

Li Y, Sun Z, Cunningham J, Aubry M, Wampfler J, Croghan G . Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res. 2011; 17(11):3830-40. PMC: 3124814. DOI: 10.1158/1078-0432.CCR-10-2877. View

11.

Keshet Y, Seger R . The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol. 2010; 661:3-38. DOI: 10.1007/978-1-60761-795-2_1. View

12.

Kong L, Chua K, Sim W, Ng H, Bi C, Ho J . MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Mol Cancer Ther. 2015; 14(7):1750-60. DOI: 10.1158/1535-7163.MCT-15-0062. View

13.

Grossi V, Peserico A, Tezil T, Simone C . p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol. 2014; 20(29):9744-58. PMC: 4123363. DOI: 10.3748/wjg.v20.i29.9744. View

14.

Puzone R, Pfeffer U . SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers. Eur J Hum Genet. 2016; 25(3):384-387. PMC: 5315515. DOI: 10.1038/ejhg.2016.179. View

15.

Zhao B, Sun Y, Wang S, Duan L, Huo Q, Ren F . Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One. 2013; 8(8):e71071. PMC: 3744527. DOI: 10.1371/journal.pone.0071071. View

16.

Berger M, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y . Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol. 2017; 28(11):2780-2785. PMC: 5834083. DOI: 10.1093/annonc/mdx412. View

17.

Tapper W, Hammond V, Gerty S, Ennis S, Simmonds P, Collins A . The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res. 2008; 10(6):R108. PMC: 2656905. DOI: 10.1186/bcr2213. View

18.

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A . Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014; 5:e1257. PMC: 4047912. DOI: 10.1038/cddis.2013.428. View

19.

Ward L, Kellis M . HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2011; 40(Database issue):D930-4. PMC: 3245002. DOI: 10.1093/nar/gkr917. View

20.

Johnson G, Lapadat R . Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298(5600):1911-2. DOI: 10.1126/science.1072682. View